McLeod HL - Search Results

1

Irinotecan pathway genotype analysis to predict pharmacokinetics.

Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL. Mathijssen RH, et al. Among authors: mcleod hl. Clin Cancer Res. 2003 Aug 15;9(9):3246-53. Clin Cancer Res. 2003. PMID: 12960109

2

Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.

McLeod HL, Murray LS, Wanders J, Setanoians A, Graham MA, Pavlidis N, Heinrich B, ten Bokkel Huinink WW, Wagener DJ, Aamdal S, Verweij J. McLeod HL, et al. Br J Cancer. 1996 Dec;74(12):1944-8. doi: 10.1038/bjc.1996.657. Br J Cancer. 1996. PMID: 8980394 Free PMC article. Clinical Trial.

3

Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors.

Rooney PH, Stevenson DA, Marsh S, Johnston PG, Haites NE, Cassidy J, McLeod HL. Rooney PH, et al. Among authors: mcleod hl. Cancer Res. 1998 Nov 15;58(22):5042-5. Cancer Res. 1998. PMID: 9823306

4

Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations.

Marsh S, Collie-Duguid ES, Li T, Liu X, McLeod HL. Marsh S, et al. Among authors: mcleod hl. Genomics. 1999 Jun 15;58(3):310-2. doi: 10.1006/geno.1999.5833. Genomics. 1999. PMID: 10373329

5

Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer.

Marsh S, McKay JA, Cassidy J, McLeod HL. Marsh S, et al. Among authors: mcleod hl. Int J Oncol. 2001 Aug;19(2):383-6. doi: 10.3892/ijo.19.2.383. Int J Oncol. 2001. PMID: 11445856

6

Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.

Wang W, Marsh S, Cassidy J, McLeod HL. Wang W, et al. Among authors: mcleod hl. Cancer Res. 2001 Jul 15;61(14):5505-10. Cancer Res. 2001. PMID: 11454699

7

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.

Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ, Pinedo HM. Peters GJ, et al. Among authors: mcleod hl. Biochim Biophys Acta. 2002 Jul 18;1587(2-3):194-205. doi: 10.1016/s0925-4439(02)00082-0. Biochim Biophys Acta. 2002. PMID: 12084461 Free article. Review.

8

Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.

Xu G, Zhang W, Ma MK, McLeod HL. Xu G, et al. Among authors: mcleod hl. Clin Cancer Res. 2002 Aug;8(8):2605-11. Clin Cancer Res. 2002. PMID: 12171891

9

SNP databases and pharmacogenetics: great start, but a long way to go.

Marsh S, Kwok P, McLeod HL. Marsh S, et al. Among authors: mcleod hl. Hum Mutat. 2002 Sep;20(3):174-9. doi: 10.1002/humu.10115. Hum Mutat. 2002. PMID: 12203989

10

Thymidylate synthase pharmacogenetics in colorectal cancer.

Marsh S, McLeod HL. Marsh S, et al. Among authors: mcleod hl. Clin Colorectal Cancer. 2001 Nov;1(3):175-8; discussion 179-81. doi: 10.3816/CCC.2001.n.018. Clin Colorectal Cancer. 2001. PMID: 12450432 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

591 results

Search Page

Filters